Meeting
2022 ASCO Annual Meeting
Primary analysis of MUKDEN 01: A multicenter, single-arm, prospective, phase 2 study of neoadjuvant treatment with pyrotinib and letrozole plus dalpiciclib in triple-positive breast cancer.
Authors
Nan Niu
Shengjing Hospital of China Medical University, Shenyang, China
Nan Niu , Fang Qiu , Tong Liu , Wenbin Guo , Guijin He , Yi Zhao , Yong Li , Dianlong Zhang , Zhigao Li , Peili Zhang , Yuanxi Huang , Gangling Zhang , Ke Li , Hongbin Han , Zhengang Cai , Pengfei Li , Hong Xu , Huajun Li , Xinyu Zheng , Caigang Liu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Clinical Trial Registration Number
NCT04486911
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 588)
DOI
10.1200/JCO.2022.40.16_suppl.588
Abstract #
588
Poster Bd #
359
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
WUTSUP-02-II-Neo-Dis-Tis: Investigating the efficacy and safety of neoadjuvant tislelizumab plus disitamab vedotin with adjuvant tislelizumab in upper urinary tract carcinoma—A phase II multi-center study.
First Author: Yige Bao
Poster
2023 ASCO Annual Meeting
Updated results from a phase 2 study on dalpiciclib and pyrotinib, a dual-oral chemotherapy-free regimen in HER2-positive advanced breast cancer (DAP-HER-01).
First Author: Min Yan
Poster
2023 ASCO Annual Meeting
Neoadjuvant HER2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP): An open label randomized phase II trial.
First Author: Heather L. McArthur
Poster
2023 ASCO Annual Meeting
A prospective, phase II, neoadjuvant clinical study based on chemotherapy sensitivity in hormone receptor–positive, HER2-negative breast cancer: FINEST study.
First Author: Li Chen